Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | USP2 | O75604 | 7/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6691770 | 0.81 | — | — | |
| SCHEMBL5491001 | 0.78 | NPC1 (0.42) | TSHRCYP3A4CYP2D6ALDH1A1USP2 | |
| SCHEMBL8049780 | 0.76 | HCRTR1 (0.46) | ALDH1A1USP2 | |
| SCHEMBL9734007 | 0.73 | — | — | |
| SCHEMBL9734009 | 0.73 | — | — | |
| SCHEMBL15392534 | 0.73 | — | — | |
| SCHEMBL19614453 | 0.72 | GRIN2B (0.39) | USP2SMN1; SMN2HPGD | |
| SCHEMBL19614479 | 0.72 | GRIN2B (0.39) | USP2SMN1; SMN2HPGD | |
| SCHEMBL15924562 | 0.72 | GRIN2B (0.39) | USP2SMN1; SMN2HPGD | |
| SCHEMBL14673362 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198722-A1 | Collections of compounds | SPIROGEN LIMITED (GB) | 2004-10-07 | — | — | US | disclosed |
| US-6747144-B1 | TREATING NEOPLASTIC DISEASES, ALZHEIMER'S DISEASE, BACTERIAL INFECTIONS, PARASITIC INFECTIONS OR VIRAL INFECTIONS | SPIROGEN LIMITED (GB) | 2004-06-08 | — | — | US | disclosed |
| EP-1107970-A2 | COLLECTIONS OF COMPOUNDS | Spirogen Limited (GB) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012509-A2 | COLLECTIONS OF COMPOUNDS | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198722-A1 | Collections of compounds | CBR3, H1-3, H1-0 | TSHR 364/4885CYP3A4 3091/4885CYP2D6 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.